BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 14576498)

  • 1. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT; Schmidt CM
    Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
    Schmidt CM; Wang Y; Wiesenauer C
    J Gastrointest Surg; 2003 Dec; 7(8):1024-33. PubMed ID: 14675712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
    Rice PL; Goldberg RJ; Ray EC; Driggers LJ; Ahnen DJ
    Cancer Res; 2001 Feb; 61(4):1541-7. PubMed ID: 11245463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
    Cusimano A; Foderà D; D'Alessandro N; Lampiasi N; Azzolina A; Montalto G; Cervello M
    Cancer Biol Ther; 2007 Sep; 6(9):1461-8. PubMed ID: 18424914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.
    Rice PL; Washington M; Schleman S; Beard KS; Driggers LJ; Ahnen DJ
    Cancer Res; 2003 Feb; 63(3):616-20. PubMed ID: 12566304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.
    Yip-Schneider MT; Wiesenauer CA; Schmidt CM
    J Gastrointest Surg; 2003; 7(3):354-63. PubMed ID: 12654560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
    Yip-Schneider MT; Nakshatri H; Sweeney CJ; Marshall MS; Wiebke EA; Schmidt CM
    Mol Cancer Ther; 2005 Apr; 4(4):587-94. PubMed ID: 15827332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
    Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM
    J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Fukazawa H; Noguchi K; Murakami Y; Uehara Y
    Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1.
    Ding XZ; Adrian TE
    Biochem Biophys Res Commun; 2001 Mar; 282(2):447-53. PubMed ID: 11401480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells.
    Elder DJ; Halton DE; Playle LC; Paraskeva C
    Int J Cancer; 2002 May; 99(3):323-7. PubMed ID: 11992399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
    Hu Y; Bally M; Dragowska WH; Mayer L
    Mol Cancer Ther; 2003 Jul; 2(7):641-9. PubMed ID: 12883037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
    Yip-Schneider MT; Sweeney CJ; Jung SH; Crowell PL; Marshall MS
    J Pharmacol Exp Ther; 2001 Sep; 298(3):976-85. PubMed ID: 11504793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
    Guha S; Lunn JA; Santiskulvong C; Rozengurt E
    Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.